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Background: The successful Greater Green Triangle Diabetes Prevention Program (GGT DPP), a small
implementation trial, has been scaled-up to the Victorian state-wide ‘Life!’ programme with over 10,000 individuals
enrolled. The Melbourne Diabetes Prevention Study (MDPS) is an evaluation of the translation from the GGT DPP to
the Life! programme. We report results from the preliminary phase (pMDPS) of this evaluation.
Methods: The pMDPS is a randomised controlled trial with 92 individuals aged 50 to 75 at high risk of developing
type 2 diabetes randomised to Life! or usual care. Intervention consisted of six structured 90-minute group sessions:
five fortnightly sessions and the final session at 8 months. Participants underwent anthropometric and laboratory
tests at baseline and 12 months, and provided self-reported psychosocial, dietary, and physical activity measures.
Intervention group participants additionally underwent these tests at 3 months. Paired t tests were used to analyse
within-group changes over time. Chi-square tests were used to analyse differences between groups in goals met at
12 months. Differences between groups for changes over time were tested with generalised estimating equations
and analysis of covariance.
Results: Intervention participants significantly improved at 12 months in mean body mass index (−0.98 kg/m2,
standard error (SE) = 0.26), weight (−2.65 kg, SE = 0.72), waist circumference (−7.45 cm, SE = 1.15), and systolic blood
pressure (−3.18 mmHg, SE = 1.26), increased high-density lipoprotein-cholesterol (0.07 mmol/l, SE = 0.03), reduced
energy from total (−2.00%, SE = 0.78) and saturated fat (−1.54%, SE = 0.41), and increased fibre intake (1.98 g/1,000
kcal energy, SE = 0.47). In controls, oral glucose at 2 hours deteriorated (0.59 mmol/l, SE = 0.27). Only waist
circumference reduced significantly (−4.02 cm, SE = 0.95).
Intervention participants significantly outperformed controls over 12 months for body mass index and fibre intake.
After baseline adjustment, they also showed greater weight loss and reduced saturated fat versus total energy
intake.
At least 5% weight loss was achieved by 32% of intervention participants versus 0% controls.
Conclusions: pMDPS results indicate that scaling-up from implementation trial to state-wide programme is
possible. The system design for Life! was fit for purpose of scaling-up from efficacy to effectiveness.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12609000507280
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The Greater Green Triangle Diabetes Prevention Project
(GGT DPP) was the first Australian implementation trial
demonstrating that a lifestyle modification programme
could be effectively implemented in a primary care set-
ting, resulting in an estimated 40% diabetes risk re-
duction [1]. Following this success and a subsequent
Healthy Living Course DPP randomised control trial [2],
the Victorian government in 2007 announced funding
for the Life! Taking Action on Diabetes (Life!) pro-
gramme, a state-wide group-based lifestyle intervention
targeting 25,000 Victorian residents aged over 50 at high
risk of type 2 diabetes (T2DM) [3]. Programme goals are
based on modifications to diet and physical activity. The
Life! programme has direct lineage from the Finnish
Diabetes Prevention Study [4], the Good Ageing in Lahti
region Implementation trial [5] and the GGT DPP [1].
Over 10,000 people have enrolled in Life! courses, run
by 208 group facilitators employed by 178 providers in
Victoria (population 4,932,422 [6], area 237,629 km2).
Moving from trials to large-scale implementation has
long been fraught with failure [7], so evaluation of the
scaled-up programme is important to assess its outcome.
The Melbourne Diabetes Prevention Study (MDPS) is an
evaluation of the effectiveness and cost-effectiveness of
the Life! programme while it is being rolled out state-
wide. This evaluation is being undertaken to see the ef-
fect of scaling-up to state level from the small GGT DPP
implementation trial.
The specific objectives of the MDPS are to evaluate a
structured primary-care based diabetes prevention
programme (Life!) being implemented in Victoria for
people aged over 50 at high risk of developing T2DM
by: monitoring clinical and behavioural outcomes before
and after the intervention (particularly reduction in dia-
betes risk, weight loss and quality of life); comparing the
Life! programme with another cohort receiving usual
care; and undertaking an economic assessment of the
Life! programme.
The MDPS was designed to recruit 1,300 individuals
(650 intervention, 650 control) from a number of
sources including primary healthcare practices and the
general community. The simultaneous large-scale rollout
of the Life! programme in the community meant that
the Life! implementers had to address issues such as re-
cruitment, changes to eligibility criteria, referral processes,
structure and content, as well as alternative programme
delivery for different population groups. This compli-
cated our evaluation of the Life! programme. For these
reasons the initial phase of the MDPS was converted to a
preliminary pilot study (pMDPS). We present here the
effectiveness results from the pMDPS. The information
obtained from this pilot phase was then used to inform a
subsequent larger MDPS that has now commenced.Archived at Flinders UniversiMethods
Trial design
The pMDPS is a prospective, open, randomised con-
trolled trial to assess effectiveness of a structured
primary-care based diabetes prevention programme im-
plemented in Victoria for people aged over 50 at high
risk of developing T2DM. This is a parallel group study,
with the intervention group receiving a diabetes preven-
tion programme (Life!) and the control group receiving
usual care.
Participants
Individuals between 50 and 75 years at high T2DM risk
were eligible to participate. High risk was defined as
scoring 15 or above on the AUSDRISK tool, a 10-item
questionnaire assessing T2DM risk [8]. Scores 15 to 19,
and 20 and above respectively result in approximately
one in seven and one in three developing T2DM within
5 years.
Exclusion criteria were diagnosed diabetes, cancer, se-
vere mental illness, substance abuse, recent myocardial
infarction, pregnancy, difficulty with spoken and written
English, belonging to a cultural group for whom the
AUSDRISK test is not calibrated [8] and other house-
hold members involved in study.
Recruitment
During 2009 and 2010, 99 individuals were recruited
from a number of sources including primary healthcare
practices. Patients with impaired glucose tolerance or
impaired fasting glucose were identified and contacted,
and others were screened opportunistically in waiting
rooms. Additional recruitment occurred at community
events (see Figure 1).
Informed consent
Informed consent was obtained in accordance with re-
quirements of Deakin University Human Research Ethics
Committee (Project Code 2009–066).
Randomisation
pMDPS participants were individually randomised to an
intervention (Life! programme) or control group. Ran-
domisation was generated by a random number table
and placed in individual sealed, opaque envelopes.
Intervention
The intervention was a series of six structured group
sessions. The first five sessions were at 2-week inter-
vals and the final sixth session was 8 months after the
first [1].
Control subjects continued with usual care provided by
their general practitioner and were subsequently offered
the Life! programme after 12 months.ty: dspace.flinders.edu.au
99 participants
92 participants randomised
7 participants excluded:
-     6 diagnosed with T2DM
-     1 with Alzheimer’s disease
38 completed
(intervention arm)
42 completed
(control arm)
49 randomised into
intervention arm
43 randomised into
control arm
n=11 dropped out n=1 dropped out
Figure 1 Participants in the preliminary Melbourne Diabetes Prevention Study.
Janus et al. Trials 2012, 13:152 Page 3 of 6
http://www.trialsjournal.com/content/13/1/152Certified and accredited Life! facilitators (trained health
professionals such as nurses or diabetes educators) de-
livered the intervention. A physiotherapist or exercise
physiologist and a dietitian co-facilitated sessions three
and four, respectively [9,10].
The Finnish Diabetes Prevention Study goals were
used [4]: no more than 30% energy from fat; no more
than 10% energy from saturated fat; at least 15 g/1,000
kcal fibre; at least 30 minutes/day moderate intensity
physical activity; and at least 5% body weight reduction.
Processes and detailed goals for lifestyle change were
individually tailored using a problem-solving and goal-
setting approach.
Measures
Participants in both groups underwent anthropometric
and laboratory tests at baseline and 12 months (weight,
height, body mass index, waist and hip circumference,
blood pressure, triglycerides, total cholesterol, low-
density lipoprotein-cholesterol, high-density lipoprotein-
cholesterol, fasting plasma glucose, 2-hour oral glucose
tolerance test (OGTT), and glycated haemoglobin).
Intervention group participants additionally underwent
these tests, except OGTT, at 3 months. Participants pro-
vided self-reported measures of depression and anxiety
(Hospital Anxiety and Depression Scale) [11], and fat
and fibre consumption (Food Frequency Questionnaire)
[12]. The primary outcomes under investigation are
changes in diabetes and CVD risk as determined by
changes in weight, waist circumference, fasting plasmaArchived at Flinders Universiand 2-hour glucose, blood pressure and lipids. The sec-
ondary outcomes include changes in lifestyle behaviour
and the Hospital Anxiety and Depression Scale depres-
sion score.
Statistical methods
Statistical analyses were conducted in Stata 11.2 (College
Station, Texas, United States) and PASW Statistics
18.0.3 (IBM SPSS. Armonk, New York, United States).
Two-sided paired t tests were used to analyse within-
group changes over time. Chi-square tests were used to
analyse differences between groups in goals met at 12
months. Differences between groups for changes over 12
months were originally analysed using analysis of covari-
ance, adjusted for baseline values. Subsequently, general-
ised estimating equations (GEE) were used to satisfy the
intention-to-treat principle, including 3-month data (col-
lected for intervention only) in the model. Quasi-
likelihood under the independence model criterion was
used to determine the best working correlation struc-
ture. P values (Table 1) are from GEE, and analysis of
covariance results are presented in the text.
Estimated diabetes risk reduction was based on waist
circumference and weight change separately using
results from two clinical trials [13-15]. In this study and
in comparator trials, the mean difference between in-
tervention and control as a percentage of the sample
size-weighted baseline mean was calculated. Separate es-
timated risk reductions for this study were then found by
assuming a simple linear relationship between percentagety: dspace.flinders.edu.au
Table 1 Changes over time by treatment arm
Intervention Control Intervention vs. control
Baseline Δ3 months Δ12 months Baseline Δ12 months Δ12 months
n Mean (SD) Mean (SE) Mean (SE) n Mean (SD) Mean (SE) Mean (SE) P value
BMI (kg/m2) 38 31.4 (4.82) −0.86 (0.15)* −0.98 (0.26)* 41 30.1 (4.19) −0.21 (0.12) −0.77 (0.29) <0.001
Weight (kg) 38 87.2 (12.5) −2.38 (0.40)* −2.65 (0.72)* 41 81.8 (14.4) −0.60 (0.33) −2.05 (0.79) 0.844
Waist (cm) 38 106.5 (8.35) −5.04 (1.00)* −7.45 (1.15)* 41 101.7 (11.52) −4.02 (0.95)* −3.42 (1.48) 0.334
Hip (cm) 38 112.7 (9.24) −1.97 (0.88)* −3.18 (1.26)* 41 110.8 (9.90) 0.37 (1.05) −3.56 (1.63) 0.348
SBP (mmHg) 38 135.9 (18.61) −6.63 (2.25)* −6.55 (2.39)* 41 132.1 (14.04) −0.45 (2.86) −6.10 (3.75) 0.126
DBP (mmHg) 38 80.1 (7.85) −1.25 (1.31) 0.70 (1.55) 41 78.4 (7.84) 1.43 (1.75) −0.73 (2.35) 0.963
TC (mmol/l) 37 4.97 (1.15) −0.08 (0.10) −0.09 (0.12) 39 5.05 (0.88) 0.06 (0.15) −0.15 (0.19) 0.225
TG (mmol/l) 37 1.41 (0.50) −0.07 (0.12) −0.09 (0.08) 39 1.44 (0.64) 0.01 (0.08) −0.10 (0.11) 0.227
HDL-cholesterol (mmol/l) 37 1.43 (0.35) 0.01 (0.03) 0.07 (0.03)* 39 1.59 (0.48) −0.05 (0.04) 0.12 (0.05) 0.259
LDL-cholesterol (mmol/l) 37 2.89 (1.01) 0.11 (0.15) −0.12 (0.11) 39 2.79 (0.84) 0.11 (0.12) −0.23 (0.17) 0.207
FPG (mmol/l) 37 5.17 (0.44) −0.07 (0.08) −0.03 (0.06) 39 5.17 (0.44) 0.05 (0.07) −0.08 (0.10) 0.219
2-hour OGTT (mmol/l) 36 6.64 (1.76) n/a −0.11 (0.30) 37 6.08 (1.50) 0.59 (0.27)* −0.70 (0.40) 0.232
HbA1c (%) 37 5.86 (0.30) −0.05 (0.03) 0.08 (0.07) 39 5.89 (0.33) 0.13 (0.08) −0.05 (0.11) 0.218
HADS-A 38 6.08 (3.35) −0.53 (0.45) −0.68 (0.38) 41 5.15 (3.18) 0.08 (0.34) −0.76 (0.51) 0.467
HADS-D 38 3.16 (2.35) 0.03 (0.36) 0.18 (0.34) 41 2.90 (2.84) 0.02 (0.27) 0.17 (0.43) 0.876
Total fat (%) 33 36.3 (4.45) n/a −2.01 (0.83)* 37 36.2 (4.51) −0.42 (0.77) −1.59 (1.13) 0.290
Saturated fat (%) 33 14.6 (3.25) n/a −1.64 (0.51)* 37 14.0 (2.93) 0.29 (0.38) −1.94 (0.62) 0.088
Fibre (g/day) 33 13.6 (2.97) n/a 1.95 (0.58)* 37 13.5 (3.32) 0.51 (0.47) 1.45 (0.75) 0.030
Δ, change over time; SD, standard deviation; SE, standard error; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total
cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FPG, fasting plasma glucose; OGTT, oral glucose tolerance test glucose
level; HbA1c, glycated haemoglobin; HADS-A, Hospital Anxiety and Depression Scale anxiety score; HADS-D, Hospital Anxiety and Depression Scale depression
score; Total fat, percentage energy from total fat; saturated fat, percentage energy from saturated fat; fibre, grams of fibre per 1,000 kilocalories of energy; n/a, not
measured at 3 months. *P<0.05 for within-group comparison.
Table 2 Baseline characteristics of the participants
Characteristic Intervention Control
Overall 38 (47.5%) 42 (52.5%)
Gender
Male 17 (44.7%) 10 (23.8%)
Female 21 (55.3%) 32 (76.2%)
Income
Low 20 (54.1%) 29 (74.4%)
Medium 15 (40.5%) 9 (23.1%)
High 2 (5.4%) 1 (2.6%)
Aboriginal or Torres Strait Islander
Yes 0 (0.0%) 0 (0.0%)
No 34 (100.0%) 38 (100.0%)
Age (years) 64.2 (7.5) 65.0 (6.0)
Education (years) 11.9 (3.2) 11.1 (2.9)
Data presented as n (%) or mean (standard deviation).
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studies. The overall estimated diabetes risk reduction
is the sample size-weighted mean of the previous two
estimates.
Results and discussion
After exclusion of seven individuals (six with newly diag-
nosed T2DM at baseline OGTT), 92 participants were
randomised (n= 49 intervention, n= 43 control) – of
whom 80 (n= 38 intervention, n= 42 control) completed
the study (Figure 1). Information at 12 months was
available for 38 intervention and 42 control participants.
Baseline characteristics are shown in Table 2. The con-
trol group contained a higher proportion of women and
lower-income individuals.
Main outcomes are shown in Table 1. Despite ran-
domisation, differences between intervention and con-
trol subjects were observed in some baseline measures,
especially weight, waist circumference and OGTT glu-
cose at 2 hours.
The intervention group showed significant reductions
at both 3 and 12 months in mean body mass index,
weight, waist and hip circumferences and systolic blood
pressure. Significant improvements were also seen at 12
months in high-density lipoprotein-cholesterol and allArchived at Flinders Universidiet measures. In control subjects, OGTT glucose at 2
hours deteriorated and only waist circumference reduced
significantly.
The intervention group significantly outperformed
control subjects in changes over 12 months for body
mass index reduction and fibre intake according to GEE
results. After adjusting for baseline in analysis ofty: dspace.flinders.edu.au
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mates, except that the intervention group also showed
greater weight loss and reduction in saturated fat intake
(P= 0.035 and P= 0.003, respectively; data not shown).
Although other differences were not significant, all
favoured the intervention group, apart from Hospital
Anxiety and Depression Scale depression score.
Table 3 shows goal attainment. Intervention partici-
pants were more likely to achieve at least one goal
(P= 0.013). At least 5% weight loss was achieved by 32%
of the intervention group compared with none of the
controls. Few attained the physical activity goal. While
there were favourable improvements in total and satu-
rated fat and fibre consumption (Table 1) towards goals,
only the fibre-intake goal (at least 15 g/1,000 kcal en-
ergy) was frequently achieved (Table 3).
Conclusions
This preliminary study shows that it is possible to scale-
up from an implementation trial for diabetes prevention
(GGT DPP) and from the Victorian-based Healthy Liv-
ing Course DPP [2] to a state-wide programme (Life!)
with comparable outcomes. The results are tending to
show that the system design for Life! will be fit for the
purpose of scaling-up to a state-wide programme [3],
but we will have to wait for the final MDPS results to
confirm this. Participants achieved an estimated 40%
diabetes risk reduction based on a decrease in waist cir-
cumference and 24% based on weight reduction, an out-
come comparable with GGT DPP [1] and better than
the FIN-D2D Finnish National Diabetes Prevention Pro-
gram [16] and the Good Ageing in Lahti region trial [5].
Better outcomes were seen in the intervention group
for anthropometric and biochemical measures, although
some were not statistically significant. Goal achievementTable 3 Preliminary Melbourne Diabetes Prevention
Study goals at 12 months
Goal n Intervention Control P value
<30% energy from total fat 70 7 (21.2) 5 (13.5) 0.394
<10% energy from saturated fat 70 4 (12.1) 2 (5.4) n/a
>15 g fibre/1,000 kcal energy 70 19 (57.6) 14 (37.8) 0.099
≥30 minutes/day moderate-level PA 79 4 (10.8) 4 (9.5) n/a
≥5% weight loss 79 12 (31.6) 0 (0.0) <0.001
Number of goals 69 n/a
0 7 (21.2) 18 (50.0)
1 15 (45.5) 12 (33.3)
2 5 (15.2) 6 (16.7)
3 5 (15.2) 0 (0.0)
4 1 (3.0) 0 (0.0)
5 0 (0.0) 0 (0.0)
Data presented as n (%). PA, physical activity.
Archived at Flinders Universiwas not as successful as for the GGT DPP [1], the
Finnish Diabetes Prevention Study [4] and the Good
Ageing in Lahti region trial [5].
At this stage, the small sample size has reduced the
generalisability of our findings. Groups were not particu-
larly well matched at baseline and 22% of the interven-
tion group dropped out, which may have confounded
the results. Measurement bias may also have contributed
to the high waist circumference reduction. Valuable les-
sons about methodology, especially recruitment and
quality control for anthropometric measurements, have
been learnt. These have been addressed in the forthcom-
ing MDPS, which has now commenced. One benefit of
this study was early diagnosis of six new cases of T2DM
during recruitment.
Implementation failure is commonplace [7] because
trials often provide insufficient information to facilitate
successful scale-up. Moderating variables and issues of
generalisability are frequently unreported and external
validity is untested or uncertain [17].
Specifically, the challenges of translating clinical trials
into effective population programmes have been
reported in the literature [18,19]. There has been a call
to identify the barriers to diabetes prevention in the real
world, with a special focus on identifying efficient inter-
vention methods and delivery mechanisms [19]. Add-
itionally, the importance of taking into account local
circumstances and establishing partnerships and colla-
borations across sectors has been noted [18]. This has
been achieved through the development of recommen-
dations and guidelines for prevention of T2DM [18,19].
These frameworks should be useful in our evaluation
processes as we continue with diabetes prevention in
Australia and with our evaluation of the state-wide Life!
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